The historical rank and industry rank for Jiangsu Recbio Technology Co's EV-to-FCF or its related term are showing as below:
FRA:G93'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.54 Med: 0 Max: 0
Current: -4.54
FRA:G93's EV-to-FCF is ranked worse than 100% of 460
companies
in the Biotechnology industry
Industry Median: 2.335
vs FRA:G93: -4.54
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Jiangsu Recbio Technology Co's EV-to-FCF
For the Biotechnology subindustry, Jiangsu Recbio Technology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Recbio Technology Co's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Recbio Technology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Jiangsu Recbio Technology Co's EV-to-FCF falls into.
Jiangsu Recbio Technology Co's current Enterprise Value is €442.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jiangsu Recbio Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-94.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Recbio Technology Co (FRA:G93) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Recbio Technology Co's PE Ratio (TTM) for today is calculated as:
Jiangsu Recbio Technology Co's share price for today is €0.785.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jiangsu Recbio Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.067.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Jiangsu Recbio Technology Co EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Jiangsu Recbio Technology Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:G93 has been successfully added to your 